HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more
HPGC Renmintongtai Pharmaceutical Corp (600829) - Net Assets
Latest net assets as of September 2025: CN¥2.99 Billion CNY
Based on the latest financial reports, HPGC Renmintongtai Pharmaceutical Corp (600829) has net assets worth CN¥2.99 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.02 Billion) and total liabilities (CN¥4.03 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.99 Billion |
| % of Total Assets | 42.62% |
| Annual Growth Rate | 6.75% |
| 5-Year Change | 44.61% |
| 10-Year Change | 102.43% |
| Growth Volatility | 18.43 |
HPGC Renmintongtai Pharmaceutical Corp - Net Assets Trend (1994–2024)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HPGC Renmintongtai Pharmaceutical Corp (1994–2024)
The table below shows the annual net assets of HPGC Renmintongtai Pharmaceutical Corp from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.88 Billion | +4.72% |
| 2023-12-31 | CN¥2.75 Billion | +11.72% |
| 2022-12-31 | CN¥2.46 Billion | +11.98% |
| 2021-12-31 | CN¥2.20 Billion | +10.39% |
| 2020-12-31 | CN¥1.99 Billion | +7.85% |
| 2019-12-31 | CN¥1.85 Billion | +16.92% |
| 2018-12-31 | CN¥1.58 Billion | -1.99% |
| 2017-12-31 | CN¥1.61 Billion | -2.17% |
| 2016-12-31 | CN¥1.65 Billion | +15.77% |
| 2015-12-31 | CN¥1.42 Billion | -33.89% |
| 2014-12-31 | CN¥2.15 Billion | -4.62% |
| 2013-12-31 | CN¥2.26 Billion | -2.10% |
| 2012-12-31 | CN¥2.31 Billion | +19.12% |
| 2011-12-31 | CN¥1.94 Billion | +11.33% |
| 2010-12-31 | CN¥1.74 Billion | +4.96% |
| 2009-12-31 | CN¥1.66 Billion | +0.47% |
| 2008-12-31 | CN¥1.65 Billion | +17.29% |
| 2007-12-31 | CN¥1.41 Billion | +29.76% |
| 2006-12-31 | CN¥1.08 Billion | +21.97% |
| 2005-12-31 | CN¥888.23 Million | -14.62% |
| 2004-12-31 | CN¥1.04 Billion | +85.65% |
| 2003-12-31 | CN¥560.39 Million | +6.50% |
| 2002-12-31 | CN¥526.17 Million | +5.00% |
| 2001-12-31 | CN¥501.11 Million | +7.45% |
| 2000-12-31 | CN¥466.36 Million | +10.48% |
| 1999-12-31 | CN¥422.13 Million | -1.99% |
| 1998-12-31 | CN¥430.69 Million | +1.10% |
| 1997-12-31 | CN¥426.02 Million | +2.92% |
| 1996-12-31 | CN¥413.92 Million | +0.99% |
| 1995-12-31 | CN¥409.86 Million | +0.86% |
| 1994-12-31 | CN¥406.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HPGC Renmintongtai Pharmaceutical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8169.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.20 Billion | 76.24% |
| Common Stock | CN¥579.89 Million | 20.13% |
| Other Comprehensive Income | CN¥104.55 Million | 3.63% |
| Other Components | CN¥1.00 | 0.00% |
| Total Equity | CN¥2.88 Billion | 100.00% |
HPGC Renmintongtai Pharmaceutical Corp Competitors by Market Cap
The table below lists competitors of HPGC Renmintongtai Pharmaceutical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cricut Inc
NASDAQ:CRCT
|
$201.78 Million |
|
GUANGDONG HK GR BA.HD-01
F:16H0
|
$201.90 Million |
|
Grupa Pracuj S.A.
WAR:GPP
|
$201.92 Million |
|
Kingsgate Consolidated Limited
PINK:KSKGF
|
$201.92 Million |
|
8x8 Inc Common Stock
NASDAQ:EGHT
|
$201.75 Million |
|
Guangdong Xinyaguang Cable Co
SHE:001382
|
$201.71 Million |
|
NATL BANKSHARES DL 250
F:9F2
|
$201.68 Million |
|
WONIK Materials Co.Ltd
KQ:104830
|
$201.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HPGC Renmintongtai Pharmaceutical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,751,418,223 to 2,881,186,525, a change of 129,768,302 (4.7%).
- Net income of 213,272,260 contributed positively to equity growth.
- Dividend payments of 160,411,832 reduced retained earnings.
- Other factors increased equity by 76,907,874.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥213.27 Million | +7.4% |
| Dividends Paid | CN¥160.41 Million | -5.57% |
| Other Changes | CN¥76.91 Million | +2.67% |
| Total Change | CN¥- | 4.72% |
Book Value vs Market Value Analysis
This analysis compares HPGC Renmintongtai Pharmaceutical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.52x to 2.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.70 | CN¥10.14 | x |
| 1995-12-31 | CN¥0.70 | CN¥10.14 | x |
| 1996-12-31 | CN¥0.71 | CN¥10.14 | x |
| 1997-12-31 | CN¥0.73 | CN¥10.14 | x |
| 1998-12-31 | CN¥0.74 | CN¥10.14 | x |
| 1999-12-31 | CN¥0.73 | CN¥10.14 | x |
| 2000-12-31 | CN¥0.80 | CN¥10.14 | x |
| 2001-12-31 | CN¥0.86 | CN¥10.14 | x |
| 2002-12-31 | CN¥0.91 | CN¥10.14 | x |
| 2003-12-31 | CN¥0.97 | CN¥10.14 | x |
| 2004-12-31 | CN¥1.03 | CN¥10.14 | x |
| 2005-12-31 | CN¥1.31 | CN¥10.14 | x |
| 2006-12-31 | CN¥1.65 | CN¥10.14 | x |
| 2007-12-31 | CN¥2.17 | CN¥10.14 | x |
| 2008-12-31 | CN¥2.56 | CN¥10.14 | x |
| 2009-12-31 | CN¥2.57 | CN¥10.14 | x |
| 2010-12-31 | CN¥2.75 | CN¥10.14 | x |
| 2011-12-31 | CN¥3.11 | CN¥10.14 | x |
| 2012-12-31 | CN¥3.73 | CN¥10.14 | x |
| 2013-12-31 | CN¥3.73 | CN¥10.14 | x |
| 2014-12-31 | CN¥3.61 | CN¥10.14 | x |
| 2015-12-31 | CN¥2.45 | CN¥10.14 | x |
| 2016-12-31 | CN¥2.84 | CN¥10.14 | x |
| 2017-12-31 | CN¥2.78 | CN¥10.14 | x |
| 2018-12-31 | CN¥2.72 | CN¥10.14 | x |
| 2019-12-31 | CN¥3.19 | CN¥10.14 | x |
| 2020-12-31 | CN¥3.44 | CN¥10.14 | x |
| 2021-12-31 | CN¥3.79 | CN¥10.14 | x |
| 2022-12-31 | CN¥4.25 | CN¥10.14 | x |
| 2023-12-31 | CN¥4.74 | CN¥10.14 | x |
| 2024-12-31 | CN¥4.97 | CN¥10.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HPGC Renmintongtai Pharmaceutical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.40%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.12%
- • Asset Turnover: 1.40x
- • Equity Multiplier: 2.49x
- Recent ROE (7.40%) is below the historical average (10.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 7.72% | 11.31% | 0.46x | 1.50x | CN¥-9.23 Million |
| 1995 | 3.11% | 4.80% | 0.42x | 1.55x | CN¥-28.14 Million |
| 1996 | 2.32% | 3.63% | 0.41x | 1.56x | CN¥-31.79 Million |
| 1997 | 1.98% | 2.73% | 0.46x | 1.57x | CN¥-34.18 Million |
| 1998 | 0.18% | 0.22% | 0.52x | 1.56x | CN¥-42.29 Million |
| 1999 | 0.55% | 0.60% | 0.54x | 1.68x | CN¥-39.89 Million |
| 2000 | 13.20% | 11.90% | 0.52x | 2.15x | CN¥14.91 Million |
| 2001 | 8.82% | 8.48% | 0.54x | 1.92x | CN¥-5.90 Million |
| 2002 | 1.92% | 2.01% | 0.54x | 1.77x | CN¥-42.51 Million |
| 2003 | 3.17% | 3.48% | 0.48x | 1.92x | CN¥-38.25 Million |
| 2004 | 4.45% | 4.15% | 0.34x | 3.12x | CN¥-33.28 Million |
| 2005 | 19.11% | 8.20% | 0.89x | 2.62x | CN¥69.17 Million |
| 2006 | 22.84% | 10.57% | 0.92x | 2.34x | CN¥122.68 Million |
| 2007 | 21.32% | 11.82% | 0.85x | 2.13x | CN¥142.37 Million |
| 2008 | 18.11% | 10.38% | 0.89x | 1.96x | CN¥120.56 Million |
| 2009 | 18.69% | 10.57% | 0.92x | 1.91x | CN¥129.65 Million |
| 2010 | 20.97% | 11.11% | 0.90x | 2.09x | CN¥174.61 Million |
| 2011 | 22.13% | 11.05% | 0.94x | 2.13x | CN¥218.47 Million |
| 2012 | 16.81% | 8.95% | 1.00x | 1.87x | CN¥147.45 Million |
| 2013 | 0.30% | 0.20% | 0.86x | 1.70x | CN¥-210.68 Million |
| 2014 | 1.90% | 2.29% | 0.53x | 1.57x | CN¥-169.43 Million |
| 2015 | 9.76% | 1.56% | 2.10x | 2.97x | CN¥-3.41 Million |
| 2016 | 13.63% | 2.49% | 1.87x | 2.92x | CN¥59.73 Million |
| 2017 | 15.77% | 3.17% | 1.65x | 3.00x | CN¥92.99 Million |
| 2018 | 16.32% | 3.65% | 1.60x | 2.79x | CN¥99.87 Million |
| 2019 | 14.47% | 3.20% | 1.51x | 3.00x | CN¥82.61 Million |
| 2020 | 7.29% | 1.81% | 1.34x | 3.01x | CN¥-53.99 Million |
| 2021 | 12.60% | 2.98% | 1.38x | 3.07x | CN¥57.27 Million |
| 2022 | 10.74% | 2.74% | 1.37x | 2.87x | CN¥18.11 Million |
| 2023 | 10.62% | 2.81% | 1.40x | 2.70x | CN¥17.02 Million |
| 2024 | 7.40% | 2.12% | 1.40x | 2.49x | CN¥-74.85 Million |
Industry Comparison
This section compares HPGC Renmintongtai Pharmaceutical Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HPGC Renmintongtai Pharmaceutical Corp (600829) | CN¥2.99 Billion | 7.72% | 1.35x | $201.76 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |